The medical world is ablaze with discussion surrounding retatrutide, a promising peptide currently in investigation for obesity conditions. Created by Zealand Pharma, retatrutide functions as a dual activator for both GLP-1 and GIP receptors, influencing appetite and glucose metabolism in a uniqu